胰高血糖素样肽-1受体激动剂对阻塞性睡眠呼吸暂停作用的研究现状

Research status of glucagon-like peptide-1 receptor agonists on obstructive sleep apnea

阻塞性睡眠呼吸暂停(OSA)是最常见的睡眠呼吸障碍性疾病,持续气道正压通气是治疗的金标准,但患者依从性并不高,因此,有必要探讨新的治疗策略。该病常合并多种疾病,尤其是2型糖尿病和肥胖症。已知有效的减重对于逆转OSA及其相关的合并症至关重要,但单纯依靠生活方式改变难以实现持续减重,而同时具有降糖和减重作用的药物是实现这种目标的途径。本文介绍了胰高血糖素样肽-1受体激动剂对此疾病的治疗作用。

Obstructive sleep apnea(OSA)is the most common sleep-disordered breathing disease.Continuous positive airway pressure(CPAP)is the gold standard for treatment,but compliance is suboptimal.Therefore,new therapeutic strategies need to be explored.OSA is often associated with multiple comorbidities,particularly type 2 diabetes and obesity.Effective weight loss is known to be crucial in reversing OSA and its associated comorbidities.However,sustained weight loss is difficult to achieve with lifestyle changes alone.Medications that have both hypoglycemic and weight-loss effects are one way to achieve this goal.This article discussed the therapeutic effect of glucagon-like peptide-1 receptor agonists on this disease.